Focus on illness that affects one million Americans
DANVILLE, PA – Geisinger investigator Janet Robishaw, Ph.D., has received a $1.5 million grant from the National Institutes of Health to study a key signaling pathway that is dysfunctional in Parkinson’s disease.
In the United States alone, this disorder affects one million patients who experience a host of motor symptoms, including tremor, general reduction voluntary movements (bradykinesia), and rigidity.
For Parkinson’s patients and their families, the quality of life is greatly reduced and the economic impact is estimated at $25 billion per year. Current treatment options show limited effectiveness. Although dopamine replacement therapy improves the motor symptoms, prolonged treatment often produces uncontrolled movements (dyskinesia) and altered intellectual functions.
By capitalizing on her discovery of a new mechanism to regulate movement, Dr. Robishaw said the goal of this study is to develop a more targeted, effective treatment for this debilitating disorder.
“Our finding also has important implications for treatment for learning disorders and addictive behaviors,” Dr. Robishaw, associate director and senior scientist at Geisinger Health System’s Weis Center for Research, said.
Identifying mechanism-based diagnoses and treatments represent dual goals of the precision medicine initiative instituted by the Geisinger learning health system to improve the overall health of affected patients.
One of the nation’s most innovative health services organizations, Geisinger serves more than 1.5 million patients in Pennsylvania and New Jersey. The system includes 13 hospital campuses, a nearly 600,000-member health plan, two research centers and the Geisinger Commonwealth School of Medicine. Geisinger is known for its focus on caring and innovative programs including the ProvenCare® best-practice approach to maximize quality, safety and value; ProvenHealth Navigator® advanced medical home; Springboard Health® population health program to improve the health of an entire community; ProvenExperience™ to provide refunds to patients unhappy with their care experience; and Geisinger’s MyCode® Community Health Initiative, the largest healthcare system-based precision health project in the world. With more than 215,000 volunteer participants enrolled, MyCode is conducting extensive research and returning medically actionable results to participants. A physician-led organization, with approximately 32,000 employees and more than 1,800 employed physicians, Geisinger leverages an estimated $12.7 billion positive annual impact on the Pennsylvania and New Jersey economies. Repeatedly recognized nationally for integration, quality and service, Geisinger has a long-standing commitment to patient care, medical education, research and community service. For more information, visit www.geisinger.org, or connect with us on Facebook, Instagram, LinkedIn and Twitter.